The IrsiCaixa AIDS Research Institute is an international landmark and leading centre for research into the eradication of HIV/AIDS and related diseases. Its director, Dr. Bonaventura Clotet, founded it in 1995 as a private non-profit foundation with the support of Obra Social “la Caixa” and the Department of Health of the Generalitat of Catalonia. It is based at the Hospital Germans Trias i Pujol, in Badalona (Barcelona). Over 60 investigators engaged in research, academic training and public engagement work at IrsiCaixa, in partnership with health care professionals and over 3,000 patients. This model facilitates the transfer of knowledge between the different stakeholders and promotes progress toward the eradication of HIV. IrsiCaixa also participates in clinical trials to evaluate new therapeutic strategies and collaborates with developing countries in the global struggle against the pandemic.
AELIX Therapeutics is supported by EIT Health
AELIX Therapeutics is supported by Spanish Goverment (Ministerio de Ciencia , Innovación y Universidades), Agencia Estatal de Investigación and FEDER Funds.
AELIX Therapeutics is supported by Agència per la Competititvitat de l’Empresa (ACCIÓ) and FEDER Funds.
This company is capitalized by Innvierte, an investment program of CDTI, E.P.E.